











































Prevalence of abnormal Alzheimer’s disease biomarkers in
patients with subjective cognitive decline: cross-sectional
comparison of three European memory clinic samples
Citation for published version:
Wolfsgruber, S, Molinuevo, JL, Wagner, M, Teunissen, CE, Rami, L, Coll-padrós, N, Bouwman, FH, Slot,
RER, Wesselman, LMP, Peters, O, Luther, K, Buerger, K, Priller, J, Laske, C, Teipel, S, Spottke, A,
Heneka, MT, Düzel, E, Drzezga, A, Wiltfang, J, Sikkes, SAM, Van Der Flier, WM & Jessen, F 2019,
'Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-
sectional comparison of three European memory clinic samples', Alzheimer's research & therapy, vol. 11,
no. 1. https://doi.org/10.1186/s13195-018-0463-y
Digital Object Identifier (DOI):
10.1186/s13195-018-0463-y
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Alzheimer's research & therapy
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 17. Aug. 2021
RESEARCH Open Access
Prevalence of abnormal Alzheimer’s disease
biomarkers in patients with subjective
cognitive decline: cross-sectional
comparison of three European memory
clinic samples
Steffen Wolfsgruber1,2* , José Luis Molinuevo3,4, Michael Wagner1,2, Charlotte E. Teunissen5, Lorena Rami3,
Nina Coll-Padrós3, Femke H. Bouwman6, Rosalinde E. R. Slot6, Linda M. P. Wesselman6, Oliver Peters7, Katja Luther7,
Katharina Buerger8,9, Josef Priller10, Christoph Laske11,12, Stefan Teipel13, Annika Spottke2, Michael T. Heneka1,2,
Emrah Düzel14, Alexander Drzezga15, Jens Wiltfang16,17,21, Sietske A. M. Sikkes18,19, Wiesje M. van der Flier6,18,
Frank Jessen2,20 and on behalf of the Euro-SCD working group
Abstract
Introduction: Subjective cognitive decline (SCD) in cognitively unimpaired older individuals has been recognized
as an early clinical at-risk state for Alzheimer’s disease (AD) dementia and as a target population for future dementia
prevention trials. Currently, however, SCD is heterogeneously defined across studies, potentially leading to variations
in the prevalence of AD pathology. Here, we compared the prevalence and identified common determinants of
abnormal AD biomarkers in SCD across three European memory clinics participating in the European initiative on
harmonization of SCD in preclinical AD (Euro-SCD).
Methods: We included three memory clinic SCD samples with available cerebrospinal fluid (CSF) biomaterial
(IDIBAPS, Barcelona, Spain, n = 44; Amsterdam Dementia Cohort (ADC), The Netherlands, n = 50; DELCODE
multicenter study, Germany, n = 42). CSF biomarkers (amyloid beta (Aβ)42, tau, and phosphorylated tau (ptau181))
were centrally analyzed in Amsterdam using prespecified cutoffs to define prevalence of pathological biomarker
concentrations. We used logistic regression analysis in the combined sample across the three centers to investigate
center effects with regard to likelihood of biomarker abnormality while taking potential common predictors
(e.g., age, sex, apolipoprotein E (APOE) status, subtle cognitive deficits, depressive symptoms) into account.
Results: The prevalence of abnormal Aβ42, but not tau or ptau181, levels was different across centers (64% DELCODE,
57% IDIBAPS, 22% ADC; p < 0.001). Logistic regression analysis revealed that the likelihood of abnormal Aβ42 (and also
abnormal tau or ptau181) levels was predicted by age and APOE status. For Aβ42 abnormality, we additionally observed
a center effect, indicating between-center heterogeneity not explained by age, APOE, or the other included covariates.
(Continued on next page)
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Conclusions: While heterogeneous frequency of abnormal Aβ42 was partly explained by between-sample differences
in age range and APOE status, the additional observation of center effects indicates between-center heterogeneity that
may be attributed to different recruitment procedures. These findings highlight the need for the development of
harmonized recruitment protocols for SCD case definition in multinational studies to achieve similar enrichment rates
of preclinical AD.
Keywords: Subjective cognitive decline, Preclinical Alzheimer’s disease, CSF biomarkers
Background
It is widely acknowledged that future prevention and
intervention approaches for Alzheimer’s disease (AD)
will be most effective when applied to individuals in a
disease stage prior to mild cognitive impairment (MCI)
or prodromal AD [1, 2]. As in the latest research frame-
work guidelines proposed for observational and inter-
vention studies [3], AD is defined in vivo by profiling of
biomarkers (e.g., those obtained from cerebrospinal fluid
(CSF)) grouped into those of amyloid beta deposition
(A), pathological tau (T), and those of neurodegenera-
tion (N) in the “AT(N)” system. Preclinical AD is present
if patients are cognitively unimpaired and have a bio-
marker profile of both abnormality in amyloid beta (A+)
and pathological tau markers (T+). Importantly, in this
new framework, subjective cognitive decline (SCD) is
considered indicative of a stage of transitional cognitive
decline, that is between a fully asymptomatic stage and a
cognitively impaired (MCI) stage of the disease.
Thus, SCD in cognitively unimpaired older individuals
is recognized as a pre-MCI at-risk state of AD dementia
and a target condition for future AD dementia prevention
trials. A first set of consensus criteria and research guide-
lines for operationalization of SCD have been published,
but comparability of SCD samples across different re-
search sites is still poor [4, 5]. Conditions other than AD
may cause symptoms of SCD which further promotes het-
erogeneity. This could be countered by harmonized re-
cruitment protocols including aspects of SCD that
enhance the likelihood of underlying AD [4, 5]. However,
there is currently a lack of such protocols for SCD case
definition and assessment in the context of preclinical
AD. The design of such a protocol represents a crucial
next step before applying SCD in largescale AD preven-
tion trials. To address this issue, the European initiative
on harmonization of SCD in preclinical AD (Euro-SCD)
aims to develop a harmonized multicenter, multinational
case-definition protocol of SCD which should yield com-
parable rates of preclinical AD (i.e., similar enrichment for
AD risk) across memory clinic cohorts. A first step of
EURO-SCD, presented in this study, is to retrospectively
analyze data from the memory clinic cohorts of the three
participating study partners, each recruited with their own
SCD recruitment protocols. Here, our aim was to evaluate
the extent of heterogeneity in biomarker abnormality
across the three European SCD samples and identifying
potential sources for this.
Methods
Standard protocol approvals, registrations, and patient
consent
The study protocol was approved by the Institutional
Review Boards of all participating study centers of the
Euro-SCD project. All patients provided written in-
formed consent.
Participants
We analyzed data from three ongoing memory clinic co-
horts that recruit SCD participants and collaborate
within EURO-SCD: The Amsterdam Dementia Cohort
(ADC) [6, 7], the cohort of l’Institut d’Investigacions
Biomèdiques August Pi i Sunyer Hospital Clinic Barce-
lona (IDIBAPS) [8], and the German Center for Neuro-
degenerative Diseases multicenter Longitudinal
Cognitive Impairment and Dementia Study (DELCODE)
[9]. Each cohort was asked to contribute a target num-
ber of 50 or close to 50 SCD patients with available CSF
samples. All CSF samples were then centrally analyzed
(in Amsterdam) with regard to AD biomarkers as de-
tailed below. Each cohort is briefly described below, to-
gether with its respective SCD recruitment protocol and
case definition.
Recruitment procedures and case definition of SCD in
each sample
DELCODE cohort
DELCODE is an observational longitudinal memory
clinic-based multicenter study carried out by 10 univer-
sity memory clinics, based within the German Center
for Neurodegenerative Diseases (DZNE) research infra-
structure. Baseline recruitment started in 2015 and is
ongoing. A complete description of DELCODE has been
published previously [9]. All SCD patients are referrals,
including self-referrals, and all were assessed clinically at
the respective memory clinics before entering the study.
Assessments included medical history, psychiatric and
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neurological examination, neuropsychological testing,
blood laboratory work-up, and routine magnetic reson-
ance imaging (MRI). The German version of the consor-
tium to establish a registry of Alzheimer’s disease
(CERAD) neuropsychological test battery [10], which in-
cludes the Trail-Making Test (TMT) A and B [11], was
applied at all memory centers. SCD was defined by the
presence of subjectively reported decline in cognitive
functioning, experienced as worrisome, and a test per-
formance of better than −1.5 standard deviations (SDs)
below age-, education-, and gender-adjusted normal per-
formance [12] on all subtests of the CERAD neuro-
psychological battery, in line with current SCD research
criteria [5]. Additional inclusion criteria were age ≥ 60
years, fluent German language skills, capacity to provide
informed consent, and the presence of a study partner.
Main exclusion criteria were conditions which clearly
interfere with participation in the study or the study pro-
cedures, for example significant sensory impairment,
current major depressive episode or other major psychi-
atric disorders either at baseline or in the past, and
chronic use of psychoactive compounds with sedative or
anticholinergic effects (see [9] for a full list of inclusion/
exclusion criteria).
Amsterdam Dementia Cohort (ADC)
The ADC is a cohort consisting of consecutive patients
visiting the Alzheimer Center of the VU University
Medical Center (VUmc) in Amsterdam, the Netherlands.
It has been described in detail previously [6, 7]. All SCD
patients underwent a standardized dementia screening,
including physical and neurologic examination as well as
laboratory tests and brain MRI. Cognitive assessment in-
cluded the Mini-Mental State Examination (MMSE) and
an extensive neuropsychological test battery. Diagnoses
were made in a multidisciplinary case conference.
Patients were defined as SCD when they presented with
cognitive complaints, but cognitive and laboratory inves-
tigations were normal and criteria for MCI, dementia, or
any other neurologic or psychiatric disorders known to
cause cognitive complaints were not met. Petersen’s cri-
teria were used for MCI [13], where the presence of
MCI-like objective cognitive impairment was deter-
mined by clinical judgment of the complete neuro-
psychological information rather than applying a specific
algorithm or impairment cutoff.
IDIBAPS Barcelona cohort
The biomarker cohort of the IDIBAPS Hospital Clinic
Barcelona recruited patients with SCD, MCI, and AD
dementia, as well as cognitively unimpaired participants
without cognitive complaints. It has been described in
detail previously [8].
Subjects with any neurological diagnosis, serious, or un-
stable medical condition, or with a diagnosis of major psy-
chiatric disorder including schizophrenia and major
depressive, severe somatic disease, or substance abuse
were excluded in all the groups. The clinical SCD group
comprises subjects who consulted the IDIBAPS Hospital
Clinic memory clinic for experience of subjective cognitive
decline. They presented normal scores on two screening
tests, namely MMSE and the Memory Alteration Test
(M@T) [14], and on all subtests of a neuropsychological
battery tapping cognitive domains of memory, language,
praxis, visuo-perceptive and/or visuospatial ability, and ex-
ecutive functions. Similar to DELCODE, test performance
of better than −1.5 SD below the mean of healthy con-
trols, matched for age and education, in all subtests of the
applied neuropsychological battery was required for a
study diagnosis of SCD.
CSF measures
CSF sampling and analytic procedures
CSF was obtained via lumbar puncture using a 25-gauge
needle and collected in 10-ml polypropylene tubes (Sar-
stedt, Nümbrecht, Germany) in agreement with inter-
national consensus protocols [15]. Within 2 h, CSF
samples were centrifuged at 4 °C for 10 min at 1800 g.
CSF supernatant was transferred to 0.5-ml polypropyl-
ene tubes and stored at −20 °C until further analysis
(within 2 months) for the Amsterdam samples. Samples
collected in the IDIBAPS and DELCODE cohort were
stored at −80 °C until transfer to Amsterdam for central
analysis. Commercially available enzyme-linked im-
munosorbent assays (ELISAs) (Innotest β-amyloid(1–
42), InnotestTAU-Ag, and InnotestPhosphotau(181P);
Fujirebio, Ghent, Belgium) were applied to measure
baseline amyloid beta (Aβ)42, total tau (t-tau), and tau
phosphorylated as position 181 (ptau181) as previously
described elsewhere [16, 17]. Clinical diagnosis was un-
known to the team performing the CSF analyses.
Definition of AD biomarker abnormality
For definition of AD biomarker abnormality, we applied
previously published cutoff values: abnormal CSF-Aβ42
was defined as values < 813 pg/ml [17]; abnormal CSF t-tau
was defined as values > 375 pg/ml; and CSF-ptau181 was
defined as values > 53 pg/ml [18]. Besides abnormality in
individual markers, we also report results for a CSF-based
operationalization of preclinical AD according to the most
recent National Institute on Aging and the Alzheimer’s
Association (NIA-AA) criteria [3], that is defined by the
presence of both abnormal CSF-Aβ42 and CSF-ptau181.
Clinical and neuropsychological assessment
Clinical and neuropsychological assessment was carried
out in each center following center-specific standardized
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diagnostic procedures that have been described in other
publications (ADC [6, 7], IDIBAPS [19], and DELCODE
[9]). Here, we only report the assessments relevant to
the present study. For the clinical and neuropsycho-
logical data to be used as predictors of CSF abnormality
across samples, we applied several rescaling procedures
as described below.
Assessment of neuropsychological test performance
All centers applied established neuropsychological tests
mainly covering three cognitive domains. Verbal mem-
ory was assessed with the German Version of the
CERAD wordlist [10] in DELCODE, the Dutch version
of the Rey Verbal Learning Test (RVLT) [20] in ADC,
and the Spanish version of the Free and Cued Selective
Reminding Test (FCSRT) [21] in the IDIBAPS sample.
Executive functions and speed were measured by the
TMT-A and TMT-B [11] in all three samples. Language
abilities were measured by tests of semantic verbal flu-
ency (animals) in all three samples [22]. The DELCODE
and IDIBAPS sample also applied the 15-item version of
the Boston Naming Test (BNT) [22], while a second,
verbal fluency measure (letters) was available in the
ADC sample [22].
We used center-specific normative data to derive age-,
sex-, and education-adjusted z-scores for each sample.
For each participant we then aggregated the z-score in-
formation of the available tests in the three cognitive do-
mains into a single, dichotomized variable with the
categories “evidence of subtle cognitive decline” vs. “no
evidence of subtle cognitive decline”. We derived this
variable by adapting the method proposed by Edmonds
and colleagues [23]: “evidence of subtle cognitive de-
cline” was defined by performance of more than 1 SD
below the normative mean (i.e., a z-score < −1) on at
least two out of six preselected neuropsychological mea-
sures (two of each of the three different cognitive domains
described above). For verbal memory we used the word
list delayed recall and recognition scores from the CERAD
in DELCODE and from the RVLT in the ADC sample, re-
spectively. The best equivalent to this in the IDIBAPS
sample was the FCSRT free and total recall score [24]. In
the language abilities domain, we utilized the animal flu-
ency and BNT score in IDIBAPS and DELCODE, and ani-
mal + letter fluency score in the ADC sample.
Depressive symptomatology and instrumental activities of
daily living performance
Depressive symptomatology was measured with the
15-item version of the Geriatric Depression Scale (GDS)
[25] in DELCODE and ADC where a cutoff > 5 indicates
depressive symptomatology. In IDIBAPS, depressive
symptoms were measured using the Hospital Anxiety
and Depression Scale (HADS) [26], where a cutoff > 7
indicates depressive symptomatology.
Instrumental activities of daily living (IADL) were
assessed with the Functional Activities Questionnaire
(FAQ) [27] in IDIBAPS and DELCODE and with the
Disability Assessment for Dementia (DAD) scale in the
ADC sample [28]. Due to the limited range and variance
in SCD patients on these two respective measures, we
derived a dichotomized variable with the following cat-
egories: “no IADL deficits” (fully unimpaired) vs. “subtle
IADL deficits” (mildly imperfect performance, that is a
score ≥ 1 on the FAQ or a score < 100 on the DAD,
respectively).
Statistical analysis
Statistical analyses were conducted with SPSS version
22. As this is an exploratory rather than a confirmatory
analysis, we report unadjusted p values.
Our main analysis focused on evaluating heterogeneity
of biomarker abnormality across the three subsamples
and identifying potential sources for this. In that regard,
we conducted four separate stepwise logistic regression
analyses, i.e., one analysis each for abnormal CSF-Aβ42,
CSF-tau, CSF-ptau181, and the aforementioned NIA-AA
preclinical AD definition (i.e., presence of abnormal
CSF-Aβ42 together with abnormal CSF-ptau181; [3]) as
the dependent variable, respectively.
We included the following covariates/predictors in a
forward selection procedure (p value for inclusion ≤ 0.05)
in step one: age, sex, years of education, evidence of subtle
cognitive decline, and apolipoprotein E (APOE) genotype.
For insignificant predictors we will report the chi-squared
values of the score test with the corresponding p values.
The score test, or Lagrange multiplier test, is used in for-
ward selection procedures to test for improvement of
model fit if variables are successively added to a prediction
model. If there was any cross-center heterogeneity in bio-
marker abnormality not explained by the predictors of
step one, then a categorical predictor of “study-center”
should significantly improve model fit by increasing ex-
plained variance beyond that of the covariate model.
Therefore, we entered study center as an additional pre-
dictor in a second step. This main analysis was based on a
sample of n = 132 cases (four cases with missing APOE).
In a supplementary analysis, we repeated the afore-
mentioned regression models with additional inclusion
of depressive symptomatology and subtle IADL deficits
as predictors in step one. This was based on a restricted
sample with n = 92 cases (n = 44 cases not included due
to missing data on IADL performance (n = 39), depres-
sive symptoms (n = 10), and/or APOE (n = 4); some sub-
jects had missing values on more than one of these
variables).
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Cases with missing data did not differ regarding age,
education, MMSE score, sex or (for those with missing on
depression or IADL only) APOE status, suggesting that
the assumption of a missing (completely) at random data
pattern was not violated, thus allowing for either multiple
imputation of the missing depression and IADL scale
values or a complete case analysis. For the sake of simpli-
city, we report on the latter, as a sensitivity analysis using
multiple imputation did not change the results.
Results
Descriptive statistics
Descriptive statistics of the whole sample and each sub-
sample regarding demographical, clinical, neuropsycho-
logical, and biomarker data are given in Table 1.
The mean age substantially varied between the centers,
with the ADC participants (mean ± SD, 62.9 ± 6.1 years)
being on average about 3.5 years younger than those of
IDIBAPS (66.2 ± 7.2 years) and about 8 years younger
than those of DELCODE (71.2 ± 4.8). We further ob-
served differences between the samples regarding sex
(with IDIBAPS containing a substantially higher number
of women), education, frequency of subclinical depres-
sive symptomatology, and neuropsychological variables.
Frequency of positive APOE4 status (overall 35.6%) did
not differ between the three samples. As expected,
neuropsychological performance was in the range of
cognitive normality, with average norm-adjusted z-scores
between +0.5 and −0.5 SD, in all samples. However, there
was still variation within this range as indicated by signifi-
cant between-center differences in the number of partici-
pants meeting the neuropsychological criteria [23] used to
define “evidence of subtle cognitive decline” (9.1% in IDI-
BAPS, 14.3% in DELCODE, and 42% in ADC, p = 0.001).
Regarding the CSF biomarkers, distribution for each
center in the form of boxplots is shown in Fig. 1. We
observed (pooled) frequencies of abnormal CSF-Aβ42 in
46.3%, abnormal CSF-tau in 25.7%, and abnormal
CSF-ptau181 in 40.4% of all SCD patients. CSF-defined
preclinical AD (both abnormal CSF-Aβ42 and
CSF-ptau181) was observed in 18.4%.
Between-center heterogeneity in AD biomarker
abnormality
On a descriptive level (i.e., not accounting for covariates)
only the CSF-Aβ42 levels were significantly different
across the centers, both in terms of continuous values
and frequency of abnormal CSF-Aβ42 according to the
applied cutoff (< 813 pg/ml; 64% DELCODE, 57% IDI-
BAPS, 22% ADC; p < 0.001, see Table 1 and Fig. 1).
Results of the logistic regression analyses for predic-
tion of each abnormal CSF biomarker are presented in
Table 2. Higher age and a positive APOE status (i.e., at
least one E4 allele) were associated with a higher
likelihood of CSF-Aβ42 abnormality. Sex (score test χ2(df
= 1) = 0.027, p = 0.871), years of education (score test χ
2
(df
= 1) = 0.334, p = 0.563), and evidence of subtle cognitive
decline (score test χ2(df = 1) = 0.044, p = 0.833) did not
show a significant association.
After adjusting for age and APOE status in step 1, we
observed a significant center effect, such that both IDI-
BAPS (odds ratio (OR) 5.78, 95% confidence interval
(CI) 2.14–15.6) and DELCODE (OR 6.54, 95% CI 2.14–
20.0) had similarly increased risk of abnormal Aβ42
values compared with ADC.
Higher age and positive APOE status were also associ-
ated with higher likelihood of having abnormal CSF-tau
as well as higher likelihood of fulfilling the CSF-based
preclinical AD definition. For CSF-ptau181 abnormality,
only APOE4 was a significant covariate. Other covariate
effects were not observed for these markers (for tau: sex,
score test χ2(df = 1) = 0.08, p = 0.777; years of education,
score test χ2(df = 1) = 0.014, p = 0.906; evidence of subtle
cognitive decline, score test χ2(df = 1) = 0.254, p = 0.614;
for ptau181: age, score test χ2(df = 1) = 0.474, p = 0.491; sex,
score test χ2(df = 1) = 0.074, p = 0.785; years of education,
score test χ2(df = 1) = 0.033, p = 0.857; evidence of subtle
cognitive decline, score test χ2(df = 1) = 2.45, p = 0.118; for
the CSF-based preclinical AD definition: sex, score test
χ2(df = 1) = 0.08, p = 0.777; years of education, score test
χ2(df = 1) = 0.014, p = 0.906; evidence of subtle cognitive de-
cline, score test χ2(df = 1) = 0.254, p = 0.614).
There was also no center effect for these markers (see
Table 2).
The supplementary analysis with IADL and depressive
symptomatology as additional predictors showed similar
results with regard to the effects reported above. Subtle
IADL deficits and depressive symptomatology were not
associated with likelihood of abnormality in any
biomarker.
Discussion
The aim of the present study was to compare the preva-
lence of CSF biomarker abnormality across three differ-
ent memory clinic samples that collaborate within the
Euro-SCD project and to identify predictors of abnormal
CSF from a set of variables available in all subsamples,
such as age, APOE genotype, depressive symptomatol-
ogy, and neuropsychological and IADL performance. In
addition, we determined, by testing for center effects,
whether there was significant between-center heterogen-
eity with regard to CSF abnormality after adjusting for
the aforementioned factors.
Unadjusted for any covariates, we observed signifi-
cantly different frequencies of biomarker abnormality
between the samples only for CSF-Aβ42. DELCODE had
the highest prevalence of Aβ42 abnormality (64%),
followed by IDIBAPS (57%) and ADC (22%). Results of
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the logistic regression analyses suggest that this apparent
heterogeneity in Aβ42 abnormality between the samples
was to some extent explained by age and APOE4 status,
two factors for which an association with likelihood of
amyloid pathology is already well established (e.g., [29]).
Age had a stronger influence on Aβ42 abnormality than
APOE4 status (see Table 2 for each predictor’s contribu-
tion of explained variance in R2) and the samples dif-
fered more strongly in mean age compared with
frequency of APOE4 status (see Table 1). With regard to
the aim of achieving homogeneous and enriched rates
of amyloid positivity across multiple SCD cohorts,
our results suggest that these two factors need to be
addressed in a harmonized case-definition protocol.
This could mean definition of similar age strata or a
minimum age cutoff (e.g., > 60 years) as inclusion cri-
terion while positive APOE status could be used to
define subgroups of SCD patients even further
enriched for preclinical AD. On the other hand,
APOE status can be used as a balancing factor when







ADC(n = 50) Between center differences (ANOVA/χ2)
F/χ2(df = 3) p value
Age, years 66.5 ± 7.0 71.2 ± 4.8 66.2 ± 7.2 62.9 ± 6.1 21.0 < 0.001
Education, years 12.5 ± 4.2 14.9 ± 3.4 10.3 ± 4.6 12.4 ± 3.2 15.6 < 0.001
Sex, female (%) 51.5 42.9 79.5 34.0 21.2 < 0.001
MMSE total score 28.4 ± 1.5 29.0 ± 1.0 28.0 ± 1.7 28.1 ± 1.6 6.8 0.002
FAQ scorea – 0.80 ± 1.10 1.05 ± 1.75 – – –
DAD scoreb – – – 96.70 ± 5.70 – –
Subtle IADL deficitsc (%) 45.4 46.3 47.6 42.9 0.148 0.929
Evidence of depressive symptomsd (%) 8.80 0.0 17.9 10.9 7.6 0.022
Verbal Delayed Recall, z-score −0.04 ± 1.11 0.33 ± 1.00 0.11 ± 0.98 −0.49 ± 1.17 7.5 0.001
Recognition/Cued Recall, z-score 0.27 ± 0.90 0.49 ± 0.57 0.35 ± 1.01 0.00 ± 0.96 3.8 0.025
Verbal Fluency Animals, z-score 0.00 ± 0.91 0.31 ± 0.96 0.06 ± 0.73 −0.31 ± 0.92 5.6 0.005
Verbal Fluency Lettersb, z-score – – – 0.36 ± 1.12 – –
Boston Naming a, z-score – 0.63 ± 0.65 0.30 ± 0.83 – – –
TMT-A, z-score −0.09 ± 1.04 0.30 ± 1.20 0.02 ± 0.97 −0.50 ± 0.81 7.7 0.001
TMT-B, z-score −0.15 ± 1.00 0.36 ± 1.09 −0.40 ± 1.01 −0.39 ± 0.72 9.3 < 0.001
Evidence of subtle cognitive declinee (%) 22.8 14.3 9.1 42.0 16.9 0.001
Apolipoprotein E ε4 carriers (%) 35.6 28.2 32.6 44.0 2.6 0.267
Aβ42, pg/ml 860.8 ± 298.1 740.0 ± 216.8 741.0 ± 236.2 1067.8 ± 295.9 7,8 < 0.001
Aβ42 < 813 pg/ml (%) 46.3 64.3 56.8 22.0 19.3 < 0.001
t-tau, pg/ml 352.5 ± 280.8 322.4 ± 193.4 378.5 ± 314.6 354.9 ± 312.6 0.428 0.653
t-tau > 470 pg/ml (%) 25.7 31.0 29.5 18.0 2.5 0.287
ptau181, pg/ml 55.5 ± 28.7 51.9 ± 22.4 59.2 ± 34.2 55.4 ± 28.4 0.684 0.506
ptau181 > 57 pg/ml (%) 40.4 35.7 45.5 40.0 0.853 0.653
Aβ42 and ptau181 abnormal (%) 16.2 21.4 20.5 8.0 3.9 0.141
Table shows sample description for the whole study sample and each center’s subsample of SCD participants
Values are shown as mean ± standard deviation unless otherwise indicated
Significant p values are indicated in bold typeface
Z-scores for neuropsychological variables represent age-, sex-, and education-adjusted normative values after applying center-specific norms in all study sites (see
Methods section for further details)
Aβ amyloid beta, ADC Amsterdam Dementia Cohort, ANOVA analysis of variance, DAD Disability Assessment for Dementia, DELCODE German Center for
Neurodegenerative Diseases (DZNE) multicenter Longitudinal Cognitive Impairment and Dementia Study, FAQ Functional Activities Questionnaire, GDS Geriatric
Depression Scale, HADS Hospital Anxiety and Depression Scale, IADL instrumental activities of daily living, IDIBAPS l’Institut d’Investigacions Biomèdiques August Pi
i Sunyer Hospital Clinic Barcelona, MMSE Mini-Mental State Examination, ptau181 tau phosphorylated at position 181, TMT Trail-Making Test, t-tau total tau
a Assessed only in DELCODE and IDIBAPS
b Assessed only in ADC
c Subtle IADL deficits defined as mildly imperfect performance, i.e., a score ≥ 1 on the FAQ, or a score < 100 on the DAD, respectively
d Evidence of depressive symptoms defined as a depression score above the cutoff of the applied scale (DELCODE and ADC, GDS > 5; IDIBAPS, HADS > 7)
e Evidence of subtle cognitive decline operationalized according to criteria proposed by Edmonds and colleagues (see [23] and Methods section): impaired score
of >1 SD below normative mean (i.e., z-score < −1) on two measures in different cognitive domains
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selecting samples across multiple sites since selection
of SCD samples with equal rates of APOE4 will in-
crease cross-sample homogeneity with regard to the
presence of preclinical AD.
However, even after adjusting for age and APOE sta-
tus, we did observe significant variance in the likelihood
of amyloid positivity between the centers which was of
equal magnitude other than the portion of variance ex-
plained by age and APOE (see Table 2). The presence of
this center-effect after accounting for age and APOE
suggests that there are further, unmeasured factors
which differed between centers and influenced the likeli-
hood of amyloid pathology. This may include different
referral procedures to the memory clinics across the
three countries and differences in the center-specific
SCD recruitment protocols, for example the application
of different criteria to exclude MCI. Recruitment
methods and sources of referral pose a major challenge
to standardize (e.g., due to country-specific differences
in the healthcare system) and also to quantify in a way
that their influence can be assessed and controlled for in
future studies.
Moreover, quantitative and qualitative information of
the exact nature of the SCD experience may give add-
itional, valuable information with regard to (the differ-
ences in) AD risk, as already suggested by the “SCD
plus” criteria [5, 30]. This could inform recruitment pro-
tocols for SCD case definition in research studies. In the
present study, we could not analyze this due to lack of
data since a common continuous measurement of SCD
Fig. 1 Boxplots for cerebrospinal fluid (CSF) levels in each sample of the three participating Euro-SCD centers. Values are presented in pg/ml.
Points mark individual values lying outside 1.5 times the interquartile range (25–75% percentile). Asterisks mark extreme values lying outside three
times the interquartile range. #The DELCODE and IDIBAPS sample show significantly lower levels compared with the ADC sample (p < 0.001). ADC
Amsterdam Dementia Cohort, DELCODE German Center for Neurodegenerative Diseases (DZNE) multicenter Longitudinal Cognitive Impairment
and Dementia Study, IDIBAPS l’Institut d’Investigacions Biomèdiques August Pi i Sunyer Hospital Clinic Barcelona
Table 2 Results of logistic regression analysis for prediction of abnormal CSF biomarkers across all three centers
Model/predictors OR (95% CI) p value R2 ΔR2 OR (95% CI) p value R2 ΔR2
Model variables Abnormal CSF-Aβ42 (< 813 pg/ml) Abnormal CSF-tau (> 375 pg/ml)
Step 1: covariates
Age (per 1-year increase) 1.09 1.03–1.15 0.003 0.080 0.080 1.18 1.09–1.28 < 0.001 0.187 0.187
Positive APOE ε4 status 2.34 1.10–5.00 0.028 0.126 0.046 6.20 2371–16.2 < 0.001 0.329 0.142
Step 2: center (ADC = reference) 0.001 0.271 0.145 0.562 0.339 0.010
DELCODE 6.54 2.14–20.0 0.001 0.841 0.241–2.94 0.786
IDIBAPS 5.78 2.14–15.6 0.001 1.53 0.476–4.89 0.477
Model variables Abnormal CSF-ptau181 (> 53 pg/ml) Abnormal Aβ42 and abnormal ptau181
Step 1: covariates
Age (per 1-year increase) Not selected 1.15 1.05–1.26 0.002 0.117 0.117
Positive APOE ε4 status 2.66 1.28–5.54 0.009 0.069 0.069 5.23 1.80–15.2 0.002 0.234 0.117
Step 2: center (ADC = reference) 0.728 0.075 0.006 0.393 0.255 0.021
DELCODE 0.983 0.401–2.41 0.970 1.68 0.374–7.54 0.499
IDIBAPS 1352 0.574–3.19 0.490 2.60 0.643–10.5 0.180
R2 and ΔR2 give an estimate of explained variance of the full model and each predictor’s contribution of explained variance within the model, respectively
No values are reported for nonsignificant predictor variables in step 1 of the models, as we used a forward selection process at this step
Aβ amyloid beta, ADC Amsterdam Dementia Cohort, APOE apolipoprotein E, CI confidence interval, CSF cerebrospinal fluid, DELCODE German Center for
Neurodegenerative Diseases (DZNE), IDIBAPS l’Institut d’Investigacions Biomèdiques August Pi i Sunyer Hospital Clinic Barcelona, OR odds ratio, ptau181 tau
phosphorylated at position 181
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was not available and joint analysis of differing scales
would require advanced psychometric (i.e., item-response
theory) techniques for which the sample size of the
present study was not sufficient. The association of spe-
cific questionnaire items with biomarkers of AD in SCD is
investigated in an ongoing multicohort project of the SCD
Initiative (“item analysis project” [5]). Furthermore, we
will address the relationship of the “SCD plus” features
with AD biomarkers in each of the Euro-SCD cohorts in a
future joint study. For this study, subjects will be prospect-
ively recruited at each site with a harmonized SCD case
definition protocol that also includes common assessment
of the SCD plus features.
It is further noteworthy that, besides the observed dif-
ferences in Aβ42 abnormality, the relative frequency of
those with abnormal ptau181 within the group of amyl-
oid positives was relatively equal across samples as can
be seen by comparing the frequency of Aβ42 abnormal-
ity with the frequency of combined Aβ42 and ptau181
abnormality in Table 1 (DELCODE, 64.3/21.4 = 2.85;
IDIBAPS, 56.8/20.5 = 2.77; and ADC, 22.0/8.0 = 2.75).
Thus, around every third SCD patient with amyloid ab-
normality also had abnormal ptau181 and would thus
fulfill preclinical AD criteria according to the most re-
cent guidelines [3]. At the same time, however, the total
number of subjects with ptau181 abnormality in the
ADC cohort is relatively high when seen in relation to
its overall lower amyloid positivity. This may suggest
that this sample also contained, to a higher degree, SCD
patients with tau pathology in the absence of a prototyp-
ical, amyloid-induced, AD pathological process
(“non-AD pathological change” [3]). However, this is
speculative, and potential reasons remain elusive to us at
the moment. In this regard it is also worth mentioning
that a relatively higher frequency of ptau181 abnormality
compared with Aβ42 abnormality has also been reported
in an earlier longitudinal SCD study of the ADC cohort
[31]. In this study, however, isolated increased tau/
ptau181 was not associated with future cognitive decline,
so it might be partly nonspecific.
Of note, the high prevalence of Aβ42 abnormality re-
ported here for the SCD patients from DELCODE and
IDIBAPS is higher compared with that reported for SCD
patients in earlier reports using these cohorts [8, 9].
However, this can be explained by the lower (i.e., stric-
ter) cutoffs applied in these aforementioned studies. Of
note, the cutoff for the present analysis is based on refer-
ence data from the ADC cohort, Gaussian mixture mod-
eling [16], and adjusted for cohort-nonspecific upward
drift in Innotest results [17]. Thus, it was the most
suited cutoff for our central CSF analysis and, although
leading to the aforementioned discrepancies compared
with earlier reports for DELCODE and IDIBAPS, does
not introduce a bias for the between-center analysis in
the present study. Furthermore, it has recently been
shown that differences in storage time (DELCODE re-
cruitment started more recently than ADC and IDI-
BAPS) has no clear effect on CSF Aβ42, tau, and
ptau181 values [32]. Nevertheless, we still acknowledge
that differences in CSF handling and storage or the ship-
ment of DELCODE/IDIBAPS probes to the central CSF
analysis in the ADC center may have influenced our re-
sults. However, taken together, we propose that our cen-
tral CSF analysis is a clear strength of the present study,
that is it improved the validity of our outcome data ra-
ther than posing a serious source of bias.
Subtle IADL deficits did not predict CSF biomarker
abnormality in the present sample. Of note, SCD and
MCI patients display (by definition) largely preserved
IADL functions. Therefore, the fact that we did not ob-
serve an association of subtle IADL deficits with abnor-
mal CSF markers in the present study might be due to
limitations in measurement, as the FAQ and DAD scale
are not designed to capture very subtle deficits. This is
underlined by the finding of ceiling effects (i.e., “fully un-
impaired”) in both scales. In fact, a recent study, using a
more refined IADL measure, demonstrated an increase
in IADL impairment across the spectrum from cogni-
tively normal (without subjective cognitive complaints)
to MCI, with SCD subject’s IADL performance lying in
between [33]. This further highlights the importance of
a refined characterization of very early functional deficits
in this group.
Previous studies have also shown, albeit modest, asso-
ciations between subtle cognitive performance deficits
and AD biomarkers in cognitively normal samples not
recruited through memory clinics (e.g., [34, 35]). While
in the present, memory clinic-based study the average
neuropsychological performance in each subsample was
well above the range of MCI-level impairment, we ob-
served differences regarding the frequency of subjects
classified as having evidence of subtle cognitive decline
according to the method of Edmonds and colleagues
(see Methods section and [23]). While DELCODE (14%)
and IDIBAPS (9%) had a similar rate of subjects with
evidence of subtle cognitive decline, it was considerably
higher in ADC with about 40% of subjects fulfilling the
criteria. Of note, this pattern might reflect that operatio-
nalization of MCI as an exclusion criterion in IDIBAPS
and DELCODE was very similar (i.e., based on prede-
fined impairment cutoffs). This approach differs from
that of ADC where definition of MCI was based on clin-
ical judgment of the complete neuropsychological infor-
mation rather than applying a specific algorithm or
impairment cutoff. While both are valid and commonly
used approaches to exclude MCI in the definition of
SCD [5], they may still lead to heterogeneity across the
resulting samples in terms of neuropsychological
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performance. However, despite this discrepancy, evi-
dence of subtle cognitive decline was not associated with
higher likelihood of CSF abnormality. These results are
in line with data from a large cohort study that showed
equal risk for incident AD dementia in individuals with
unimpaired memory performance but memory concerns
compared with those with a study diagnosis of “early
MCI” (i.e., conceptually similar to the subtle cognitive
decline operationalization used here) [30]. This chal-
lenges the usefulness of subtle cognitive deficits as a pre-
dictor for AD risk in pre-MCI samples. However, a
possible alternative explanation for the negative finding,
and likewise for the observed differences regarding evi-
dence of subtle cognitive decline, might be that our
operationalization relied on center-specific normative
data (and, to some extent, on nonidentical tests per do-
main in each center). The resulting z-scores thus only
represent relative deficit scores compared with each cen-
ter’s specific normative data. As a consequence, their
comparability in an absolute manner is not feasible. Lim-
ited comparability of different normative samples and
the fact that norms might be differently accurate for dif-
ferent age strata preclude this. These factors may have
stirred the between-center differences regarding the
number of SCD patients meeting the subtle cognitive
decline criteria and, likewise, may have precluded the
finding of an association between subtle cognitive per-
formance deficits and biomarker abnormality in the
present sample.
With regard to homogenous SCD sample selection,
close attention should therefore be paid to enabling a
homogenous neuropsychological characterization (ideally
including comparable norms) to enable a valid, neuro-
psychological MCI definition as an exclusion criterion
across different samples. Application of such a common
MCI criterion may further reduce heterogeneity with re-
gard to the prevalence of preclinical AD. However, this
needs to be empirically tested in a future multisite study.
Conclusions
In summary, the results of the present study emphasize
the need for harmonized SCD case-definition protocols
for future studies on intervention and prevention in this
promising target group. Age range, genetic risk factors,
and cognitive functional status are important factors to be
considered in the development of such protocols aiming
to achieve similar enrichment rates of preclinical AD.
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